Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27661989%3A_____%2F20%3A10002767" target="_blank" >RIV/27661989:_____/20:10002767 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/20:00116133 RIV/61988987:17110/20:A210263F RIV/00216208:11120/20:43920247 RIV/00159816:_____/20:00073058

Výsledek na webu

<a href="https://www.tandfonline.com/doi/pdf/10.1080/00365521.2020.1774921?needAccess=true" target="_blank" >https://www.tandfonline.com/doi/pdf/10.1080/00365521.2020.1774921?needAccess=true</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/00365521.2020.1774921" target="_blank" >10.1080/00365521.2020.1774921</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation

Popis výsledku v původním jazyce

Objectives:Body weight is one of the factors affecting blood levels of 25-hydroxyvitamin D (25OHD). The aim of this study was to establish whether a vitamin D (vitD) weight-based dosing is more appropriate to a fixed daily dose in patients with inflammatory bowel disease (IBD). Materials/methods:This was an open label randomised trial. Patients with IBD were assigned to receive oral cholecalciferol at a dose of 28 IU/kg (IU/kg) or 2000 IU per day (IU/day) for 12 weeks during winter months. 25OHD plasma levels and other biochemical parameters were measured at baseline and after supplementation period. The primary outcome measure was 25OHD level after a follow-up period. Results:A total of 173 patients were analysed. The mean BMI was 25.5 +/- 5.1 and initial mean 25OHD level was 62.7 +/- 25.5 nmol/l. A similar increase (9.7 +/- 26.9 vs 9.8 +/- 26.7 nmol/l) in 25OHD levels occurred both in IU/kg and IU/day group. The proportion of subjects with normal and sub-normal levels following the substitution was comparable irrespective of body weight. The change in 25OHD level correlated positively only with the dose of vitD (p &lt; .001) and negatively with the baseline 25OHD level (p &lt; .001). A sustained 25OHD level of 75 nmol/l corresponds with a calculated daily vitD dose of 2034 IU. Conclusions:Weight-based dosing of vitamin D is not superior to a fixed dose in order to maintain stable 25OHD levels in IBD patients. Cholecalciferol dose of 2,000 IU/day is safe and sufficient during winter period.

Název v anglickém jazyce

Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation

Popis výsledku anglicky

Objectives:Body weight is one of the factors affecting blood levels of 25-hydroxyvitamin D (25OHD). The aim of this study was to establish whether a vitamin D (vitD) weight-based dosing is more appropriate to a fixed daily dose in patients with inflammatory bowel disease (IBD). Materials/methods:This was an open label randomised trial. Patients with IBD were assigned to receive oral cholecalciferol at a dose of 28 IU/kg (IU/kg) or 2000 IU per day (IU/day) for 12 weeks during winter months. 25OHD plasma levels and other biochemical parameters were measured at baseline and after supplementation period. The primary outcome measure was 25OHD level after a follow-up period. Results:A total of 173 patients were analysed. The mean BMI was 25.5 +/- 5.1 and initial mean 25OHD level was 62.7 +/- 25.5 nmol/l. A similar increase (9.7 +/- 26.9 vs 9.8 +/- 26.7 nmol/l) in 25OHD levels occurred both in IU/kg and IU/day group. The proportion of subjects with normal and sub-normal levels following the substitution was comparable irrespective of body weight. The change in 25OHD level correlated positively only with the dose of vitD (p &lt; .001) and negatively with the baseline 25OHD level (p &lt; .001). A sustained 25OHD level of 75 nmol/l corresponds with a calculated daily vitD dose of 2034 IU. Conclusions:Weight-based dosing of vitamin D is not superior to a fixed dose in order to maintain stable 25OHD levels in IBD patients. Cholecalciferol dose of 2,000 IU/day is safe and sufficient during winter period.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Scandinavian Journal of Gastroenterology

ISSN

0036-5521

e-ISSN

1502-7708

Svazek periodika

55

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

671-676

Kód UT WoS článku

000545392100001

EID výsledku v databázi Scopus

2-s2.0-85086906005